Open AccessCOMPUTATIONAL STUDIES OF PURINE DERIVATIVE USING MULTIFORMS OF HUMAN POLYPEPTIDES 1 AS TARGET ENZYME FOR ANTICANCER AGENTS
Author(s) -
Marina Juliet A,
Hemalatha Cn,
Vijey Aanandhi M
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i9.19340
Subject(s) - pubchem , quantitative structure–activity relationship , docking (animal) , purine , protein data bank , chemistry , dock , anticancer drug , drug discovery , combinatorial chemistry , computational biology , drug , stereochemistry , enzyme , biochemistry , protein structure , biology , pharmacology , medicine , nursing
Objective: This research was conducted to prove and estimate the activity of the newly designed compound by applying quantitative structure–activity relationship (QSAR) study using Vlife molecular design suite (MDS) 2 software on various purine derivatives. These novels scaffolds/candidates, which could have the potential to inhibit 5FSO would represent promising starting points as lead compounds and certainly aid the experimental designing of anticancer drugs.Materials and Methods: Purine derivatives are studied and based on the QSAR study new structures are drawn and predicted the biological activity using the Vlife MDS Software-Module Name: QSAR Plus. Auto dock 1.2.6 software is a suite of automated docking tools. It is designed to predict how small molecules, such a substrate or drug candidates, bind to receptors of the known 3D structure. 5FSO protein preparation and optimization, ligand preparation and optimization, and docking simulations were carried out by using biological databases such as PubChem, Drug Bank, Protein Data Bank.Results: To estimate the activity, computational studies had been applied. In addition, the newly designed compound can be used as a scaffold to design more purine compounds which may be a potent inhibitor of 5FSO protein.Conclusion: The results depict as the newly designed molecules has better binding energy than standard drug and these compounds may possess better anticancer activity.